The Megyn Kelly Show this week invited Dr. Drew Pinsky to talk about two painful stories that have the nation asking hard questions: Matthew Perry’s autopsy and the still‑unfolding death of Presley Gerber at a rehab facility. Their conversation aimed to separate medical fact from the celebrity myth. It also raised one simple truth: fame and medicine do not mix well when rules are ignored.
What the coroner and federal prosecutors actually found
The coroner’s report on Matthew Perry concluded the cause of death was the “acute effects of ketamine,” with drowning, coronary artery disease, and buprenorphine listed as contributing factors. Reporters noted the ketamine level in his blood was similar to levels used for general anesthesia. Those are not opinion — those are the medical examiner’s words.
Federal prosecutors treated the case like what it was: a criminal supply chain. Multiple people were indicted and convicted for supplying ketamine and related roles. A physician who admitted supplying ketamine received a federal sentence. The dealer dubbed the “Ketamine Queen” got a long term behind bars. Perry’s former assistant was sentenced after admitting his role in obtaining and administering the drug. The Justice Department said the ketamine sold by those operators “contributed to at least two deaths, including the overdose death of Matthew Perry.” That’s accountability. It’s also what happens when the medical gatekeepers fail and the black market fills the void.
Presley Gerber and the risk inside rehab facilities
The Presley Gerber case is still under investigation and the medical examiner deferred cause and manner pending further testing. The family called themselves “beyond heartbroken,” a phrase many have repeated with respect. Reporters are asking the right questions: how did a young man die while under care, and what does oversight of treatment centers look like? These tragedies push a spotlight onto rehab facilities that promise help but sometimes offer lax supervision or worse. We must wait for the final official findings, but asking tough questions now is not cruel — it’s necessary.
Ketamine: medicine, trend, and regulatory mess
Ketamine has a double life. It’s an important anesthetic and, in tightly controlled forms like esketamine (Spravato), a regulated option for severe depression. But off‑label ketamine clinics and compounded products vary wildly in dose and monitoring. The FDA has issued compounding risk alerts. When clinics cut corners or when providers hand out high‑strength doses without proper oversight, the danger is real. Celebrity patients don’t make them safer — if anything, fame can create shortcuts and special favors that should never happen in medicine. Like Dr. Drew noted on the show, addiction is a medical problem, but it’s also an ethical one when others enable harmful access.
Here’s the plain conservative take: we should have compassion for people who struggle with addiction, including famous people. But compassion is not the same as enabling the wealthy to obtain powerful drugs absent safeguards. The DOJ did its job by prosecuting suppliers who sold lethal ketamine. Regulators should tighten rules on compounding and outpatient ketamine clinics. And the public should stop treating celebrity status as a medical passport. If you want change, demand true accountability at clinics, tougher oversight of drug compounding, and honest talk about personal responsibility. Grief and sympathy are due to the families — but so is the sober insistence that rules, not privilege, protect lives.

